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Abstract. In the present study, we investigated the role of 
matrix metalloproteinase (MMP)-2 and -9 as novel biomarkers 
in the body fluid of patients with metastatic breast cancer. We 
measured the expression of MMPs in 37 samples of body fluid 
(10 peritoneal and 27 pleural fluids) from metastatic breast 
cancer patients between 2000 and 2009. Zymography and 
ELISA assays were used to determine the cut-off level and to 
quantify MMP expression from a positive control, HT-1080 
conditioned media. MMP expression in patient samples was 
measured with ELISA and compared with other clinical 
parameters. Ascitic carcinoembryonic antigen (CEA) and 
pleural CEA were measured in patient samples with a chemi-
luminescent enzyme immunoassay. Body fluid cytology had a 
positivity of 45% (9/20) for pleural fluid and 28.6% (2/7) for 
ascites. However, MMP-2 had a positivity of 85.2% (23/27) 
in 27 pleural fluid samples and 100% (10/10) in ascitic fluid 
with cut-off levels of 8.6 and 0.14 ng/ml for MMP-2 and 
-9, respectively. When body fluid CEA and MMP-2 were 
combined, the positivity improved to 96% in pleural fluid and 
100% in ascites. MMP-2 expression in body fluid did not show 
any significant differences, but MMP-9 expression was lower 
in ascites than in pleural fluids (p<0.005). Our results suggest 
that MMP-2 expression in body fluid be used as an additive 
diagnostic marker for metastatic breast cancer patients.
Introduction
Breast cancer is one of the most common cancers in the world. 
There are 2.5 million women diagnosed with breast cancer 
in the United States, and in Europe. Additionally, 350,000 
new cases are diagnosed each year, with a mortality rate of 
130,000 patients, accounting for 17.5% of all cancer-related 
mortality in Europe (1,2). In Korea, the incidence rate for 
breast cancer has increased by 2.6% each year (3). In advanced 
adenocarcinoma, progressed or stage IV cancer, malignant 
peritoneal and pleural fluid may develop as the tumor 
progresses, and this occurs in 10% of all cases (4).
Clinically, cancer antigen (CA) 15-3 is widely used as a 
tumor marker for breast cancer, but it is mostly used with 
plasma samples. Among the diagnostic methods using body 
fluid, cytology is thought to be the most reliable, but it is limited 
by low sensitivity (5). To compensate for the low sensitivity, 
other diagnostic markers, such as carcinoembryonic antigen 
(CEA), which has been reported to have a diagnostic value for 
determining malignancy in pleural fluid, are being used clini-
cally (6). Ascitic CEA has recently been reported to have an 
increased specificity in peritoneal fluid for diagnosing gastric 
malignancy (7). However, the markers that are being used to 
diagnose malignancy still pose problems of low sensitivity 
with a wide variability, which is a limitation in routine clinical 
use, particularly for predicting prognosis (8,9).
Matrix metalloproteinases (MMPs) are known to promote 
cancer progression through extracellular matrix (ECM) and 
basement membrane degradation, resulting in the exposure 
of cryptic locations linked to invasion, metastasis and angio-
genesis (10-12). It has been reported that active MMPs are 
indicators for metastasis in breast cancer (13). Additionally, 
the overexpression of MMP-2 and -9 is reportedly correlated 
with poor overall survival, suggesting that MMP-2 and -9 are 
possible prognostic markers (11,14). Therefore, the improved 
ability to detect malignancy in body fluids of breast cancer 
patients using biomarkers such as MMPs may be helpful for 
determining the proper treatment and predicting prognosis. In 
this study, we evaluated the possibility of using MMP-2 and -9 
expressed in body fluids as diagnostic markers for metastatic 
breast cancer.
Materials and methods
Patients. We collected the body fluids of 36 patients, who were 
clinically diagnosed with metastatic stage IV breast carci-
noma with malignant ascites or pleural effusion (10 ascites, 
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27 pleural fluids; one patient had malignant ascites and pleural 
effusion) at Yonsei Cancer Center, Yonsei University College 
of Medicine, Yonsei University Health System between 
October 2000 and September 2009. Medical records were 
retrospectively reviewed for patient demographic and clinical 
information including serum CEA and CA 15-3. The patients 
had systemic metastasis with more than 2 sites of metastasis, 
including at least one site of visceral metastasis. The patients 
were heavily pretreated with systemic chemotherapy, with 
the median chemotherapy regimen consisting of 3 chemo-
therapeutic agents (range, 1-7). Clinical and radiological 
results confirmed that the body fluids originated from the 
carcinomatosis of breast cancer, with no evidence of other 
malignancies (15). When the body fluid was detected for the 
first time in each patient, it was collected through paracentesis 
or thoracentesis. Body fluid cytology based on cell block and 
routine body fluid examinations were performed and samples 
were kept at -70˚C until they were used for experimentation. 
Body fluid cytology results were available in 7 peritoneal 
and 20 pleural fluids. In addition, CEA expression from body 
fluids (aCEA for peritoneal and pCEA for pleural fluids) was 
evaluated with a chemiluminescent enzyme immunoassay 
(Beckman Coulter Inc., Minnesota, MN, USA). Following 
the previous result, a positive cut-off level of 5 ng/ml CEA for 
body fluid was used (7). Patient survival was calculated from 
the date body fluid was collected until the date of mortality due 
to any cause. Signed consent was obtained from all patients.
Positivity of body fluid MMP-2 and -9. The cut-off level for 
positivity of body fluid MMPs determined from a comparison 
of zymography and ELISA was used based on previous 
results (16). Briefly, conditioned media (CM) of HT-1080 and 
human fibrosarcoma cells, were used as a positive control for 
MMP-2 and -9. To overcome the difficulties of zymography, 
which shows the qualitative biological activity of MMPs, and 
also to quantify their activities, an ELISA assay was utilized. 
Enzymatic activity and the quantitative expression level of MMP 
were compared with the protein concentration of HT-1080 CM. 
After confirming the positive correlation between zymography 
and ELISA results (p<0.05), we determined the diagnostic 
cut-off for MMP-9 as 0.14 ng/ml and 8.6 ng/ml for MMP-2 (16). 
Patient samples were then quantified with ELISA assay.
Statistical analysis. To compare the expression levels of 
body fluid MMPs with body fluid CEA and cytology, the 
Mann-Whitney U-Test was used. In analyzing the overall 
survival, we performed a log-rank test using the Kaplan-Meier 
method. SPSS 13.0 was used to perform all statistical analyses. 
P<0.05 was considered to indicate a statistically significant 
difference.
Results
Biomarker expression in the body fluid of breast cancer 
patients. Our patient sample included only females (n=36), 
and the total sample number was 37, as one patient had both 
malignant ascitic and pleural effusion. The median age of the 
patients was 54 years (range, 36-77). Body fluid cytology had 
a 40.7% (11/27) positivity, serum CA15-3 had a mean value 
of 159.3±298.4 µg/ml, serum CEA 22.9±67.9 ng/ml, and body 
fluid CEA had a mean value of 60.9±124.1 ng/ml in all patients 
(Table I). Median overall survival of all patients was 37 days 
(range, 5-1463), suggesting that the patients had far advanced 
disease, and patients were heavily pretreated when they 
developed the malignant ascites of pleural effusion. Notably, 
our results showed that patients with peritoneal fluid had a 
significantly shorter survival, with a median of 16 days (range, 
5-792), compared to patients with pleural fluid, who had a 
median survival of 291 days (range, 10-1463), p<0.05 (Fig. 1). 
Since body fluid CEA has been reported to have a role 
as a biomarker (7), we evaluated CEA in body fluids. CEA 
Table I. Patient characteristics.
 Ascites Pleural effusion Total
Patienta   
  Female 10 27 36
Sample   
  Body fluid 10 27 37
Age, median 53 (40-64) 54 (36-77) 54 (36-77)
(range) 
Fluid CEA  124.5±213 37.3±58.8 
mean ± SD 
Serum CEA 14±16.6 31.9±76.5
mean ± SD  
Serum CA15-3 380.6±542.4 88.4±106.5
mean±SD  
Cytology   
  Positive 2 (28.6%) 9 (45%) 
  Negative 5 (71.4%) 11 (55%) 
Survivalb   
  Median (range) 16 (5-792) 291 (10-1463) 
aOne patient who has body fluids of ascites and pleural effusion is 
involved in each analysis independently. bSurvival after body fluid for-
mation. CEA, carcinoembyonic antigen; CA15-3, cancer antigen 15-3. 
Figure 1. Overall survival compared between body fluids.
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expression differed in body fluids; ascites had a higher CEA 
expression of 124.5±213 ng/ml than the CEA expression in 
pleural fluids, which was 37.3±58.8 ng/ml. We then compared 
MMP-9 and -2 expression in body fluids. Peritoneal fluid had 
a lower MMP-9 expression level of 0.09±0.26 ng/ml compared 
to 0.25±0.64 ng/ml from the pleural fluids. However, MMP-2 
expression in ascites (34.1±20 ng/ml) was higher than that in 
pleural fluids (29.9±24.5 ng/ml) (Table II). When we compared 
the expression levels of various biomarkers (CEA, MMP-2, 
MMP-9) in ascites and pleural fluids, CEA and MMP-2 were 
not significantly different (data not shown). In comparison, 
MMP-9 expression in pleural fluid was higher than that in 
peritoneal fluid (p<0.05).
Improved malignancy detection using body fluid MMP-2. 
Cytology information from 20 pleural and 7 peritoneal fluids 
showed positive rates of 45 (9/20) and 28.6% (2/7), respectively, 
demonstrating that cytology has an overall low sensitivity in 
our samples, as reported in previous studies (5,9). Following 
evaluation of other biomarkers in 27 pleural fluids, MMP-2 
was found to have the highest positivity with 85.2% (23/27), 
followed by CEA, with a 74.1% (20/27) positivity. MMP-9 
showed the lowest positivity with 29.6% (8/27) (Table III). 
Notably, in five patients with ascites and negative cytology from 
peritoneal fluid, four patients were positive for CEA expression 
(80%), one patient was positive for MMP-9 expression (20%), 
and all five patients were positive for MMP-2 expression 
(100%). By contrast, in 11 pleural fluids with negative cytology, 
the positivity for CEA, MMP-2 and MMP-9 were 63.6 (7/11), 
72.7 (8/11) and 27.3% (3/11), respectively. These results suggest 
that body fluid MMPs, especially MMP-2, could be used as 
diagnostic biomarkers in metastatic breast cancer.
When the biomarkers were combined, an increase in sensi-
tivity was observed. In pleural fluids, combining CEA and 
MMP-2 increased the positivity to 96.3% (26/27). Combining 
MMP-9 and MMP-2 showed a positive rate of 88.9% (24/27), 
combining CEA and MMP-9 improved the positivity to 85.2% 
(23/27), and combining all three markers had the same posi-
tive rate as combining just CEA and MMP-2, 96.3% (26/27) 
(Table III). In the 10 peritoneal fluid samples, MMP-2 had 
the highest positive rate with 100% (10/10), followed by CEA 
which had a positivity of 80% (8/10), and MMP-9 had the 
lowest positive rate with 10% (1/10). The combination of body 
fluid CEA and body fluid MMP-2 had a positive rate of 100% 
(10/10), which was equal to combining body fluid MMP-9 
and body fluid MMP-2 or combining all three biomarkers. 
The combination of body fluid CEA and body fluid MMP-9, 
however, increased positivity to 80% (8/10) (Table III). As a 
result, MMP-2 was more sensitive to detecting malignancy 
in body fluids and had an additional diagnostic role when 
combined with body fluid CEA.
Previous reports have suggested that body fluid CEA is a 
marker with a relatively high sensitivity of approximately 80% 
in the body fluid of various types of cancer, confirming results 
of this study, obtained from the body fluid of metastatic breast 
cancer patients (6,7,16). However, our results showed that 
body fluid MMP-2 had an even higher sensitivity than body 
fluid CEA for detecting malignancy in breast carcinoma. In 
pleural fluids, the combination of body fluid MMP-2 and body 
fluid CEA improved sensitivity to almost 100%, indicating 
that MMP-2 alone, or in addition to CEA, may be used as a 
diagnostic biomarker. In peritoneal fluid, MMP-2 had a posi-
tivity of 100%, suggesting that body fluid MMP-2 is a useful 
diagnostic biomarker in metastatic breast cancer patients, in 
addition to cytology and body fluid CEA.
Discussion
We evaluated the expression of MMP-2 and -9 in the body fluid 
of metastatic breast cancer patients to determine the possi-
bility of using MMPs as biomarkers. MMPs are reportedly 
involved in prognosis and are used as prognostic markers in 
tissue and plasma samples (17,18). Our study focused on body 
fluid samples, which have an advantage over tissue and plasma 
samples in terms of their availability and representation of the 
direct effect from cancer. Body fluids may be obtained from 
patients as soon as the fluids accumulate, but tissue samples 
are limited in their availability. Moreover, plasma samples are 
not directly in contact with the cancer, and thus may contain 
numerous non-specific target molecules, whereas body fluids 
form directly at the site of cancer and are capable of reflecting 
cancer status as well as tumor burden. Therefore, body 
Table II. Comparison of body fluid biomarker expression 
between ascites and pleural effusion.
 N MMP-9 MMP-2 CEA
Ascites 10 0.09±0.26 34.1±20 124.5±213
Pleural effusion 27 0.25±0.64 29.9±24.5 37.3±58.8
Total 37 0.20±0.56 31.1±23.19 60.9±124.1
MMP-9, matrix metalloproteinase-9; MMP-2, matrix metallopro-
teinase-2; CEA, carcinoembyonic antigen.
Table III. Positivity of single and multiple biomarkers in body 
fluids.
 Ascites Pleural fluids
 (Total n=10) (Total n=27)
 ----------------------- -------------------------
 n % n %
Single marker
  CEA 8 80 20 74.1
  MMP-9 1 10 8 29.6
  MMP-2 10 100 23 85.2
Multiple markers    
  CEA+MMP-9 8 80 23 85.2
  CEA+MMP-2 10 100 26 96.3
  MMP-9+MMP-2 10 100 24 88.9
  CEA+MMP-9+MMP-2 10 100 26 96.3
CEA, carcinoembryonic antigen; MMP-9, matrix metallopro-
teinase-9; MMP-2, matrix metalloproteinase-2.
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fluids provide advantages over tissue and plasma samples for 
understanding pathogenesis and diagnosis, and for predicting 
clinical outcomes in breast cancer.
Cytology from body fluid is known to be the most reliable 
marker for diagnosis, but has an extremely low sensitivity (5). 
Due to the low sensitivity, other cancer-related biomarkers 
such as CEA and telomerase activity are being used in patient 
samples, but still yield unsatisfactory sensitivities and speci-
ficities, and are not applicable due to difficulties in detection 
methods. We aimed to identify diagnostic biomarkers with 
increased sensitivity by evaluating MMP-2 and -9 expression 
in body fluids to be used alone or in addition to body fluid 
CEA, for detecting malignancy within body fluids from meta-
static breast cancer.
Since our study focused on assessing body fluid MMP-2 
and -9 as diagnostic markers in breast cancer, the choice of 
method for evaluation was important, as the assay directly 
affects accuracy and practicality. While zymography allows 
visualization of the enzymatic activity of MMPs qualitatively, 
ELISA provides a quantitative amount of MMP protein 
expression. The combination of methods allows us to create an 
accurate assessment of MMP expression (19). Using the two 
assays with HT-1080 CM, we determined a cut-off level for 
MMP-9 of 0.14 and 8.6 ng/ml for MMP-2 based on the minimal 
level of expression that could be sufficient for diagnosis.
In our experiment, body fluid MMP-2 had a positivity of 
85.2% in pleural fluid and 100% in peritoneal fluid. When body 
fluid MMP-2 was combined with body fluid CEA, positivity 
was increased to 96.3% in pleural fluid. Compared to body fluid 
MMP-9 with limited diagnostic features, body fluid MMP-2 
alone or in combination with body fluid CEA was useful as an 
additive diagnostic marker in the body fluid of breast cancer 
patients. Although body fluid MMPs did not seem to have 
any prognostic role in our study (data not shown), the type of 
body fluid had a prognostic role. Breast cancer patients with 
peritoneal fluid had a significantly shorter survival compared 
to patients with pleural fluid. This observation may be corre-
lated with disease burden considering the site of metastasis 
from the original breast tumor. Previously, it was reported 
that MMP-2 and MMP-9 are involved in breast cancer inva-
sion (20,21). Our results have shown that MMP-2 has a higher 
expression and positivity than MMP-9. Findings of a previous 
report that evaluated 23 malignant body fluids showed that 
MMP-2 (87%) had a higher positivity than MMP-9 (78.3%) in 
different cancer origins, corresponding with our result (22). 
In addition, MMP-9 expression was significantly higher in 
pleural than in peritoneal fluid. Breast cancer patients initially 
form pleural fluid, which may invade to cause the formation 
of peritoneal fluid in the abdomen. Since MMP-2 and -9 are 
involved in cancer invasion, MMP expression may be higher 
in pleural fluid in preparation for cancer invasion, whereas 
MMP expression may be lower in peritoneal fluid, suggesting 
that invasion has already occurred. Studies have shown that 
MMP-9 is capable of being downregulated after invasion and 
body fluid formation has occurred, suggesting that MMP-9 
expression is tightly controlled, which may contribute to the 
low level of MMP-9 in peritoneal fluid (23,24). In one patient 
who had both ascitic fluid and pleural effusion, MMP-9 
expression in the pleural fluid (0.55 ng/ml) was much greater 
than that in the ascitic fluid (0.02 ng/ml).
Previous reports determined that cancer invasion is corre-
lated with poor survival (25). We observed that the patients 
with malignant ascites showed a shorter survival compared to 
the patients with pleural effusion. As pleural and peritoneal 
effusions occur in various parts of the body with different 
biology, we consider that the body fluid itself may differ in 
the expression and biological role of each molecule, which 
may also predict prognosis. Previous reports have suggested 
that MMP-9 and MMP-2 overexpression correlates with 
poor overall survival in tissue and plasma samples of various 
cancers (17,18). However, results from our experiment did not 
concur with these reports, except for the prognostic potential 
of the site of malignant effusion. This may be related to the 
small sample size in our study. Moreover, since our study used 
body fluid, rather than tissue and plasma, the expression of 
MMPs may differ, since MMPs are under tight control in the 
body and in cells (23,24).
Although we focused on the role of body fluid biomarkers, 
if we could use the serum biomarkers in addition to the body 
fluid biomarkers, more reliable information would be obtained 
in order to understand the status of the patients, including 
tumor burdens and prognosis. Among the numerous tumor 
markers, serum CEA and CA 15-3 are mostly used for breast 
cancer patients. However, in our patient set, the level of those 
serum markers were not correlated with each other or with 
body fluid biomarkers. In addition, pleural CEA has been used 
for the detection of malignancy from pleural fluid. However, 
ascitic CEA has recently been suggested as a detection factor 
for malignancy by our previous report in gastric cancer. 
Therefore, in this study we compared ascitic and pleural 
CEA with body fluid MMPs. Our study was unique in that it 
analyzed MMP expression in body fluids of metastatic breast 
cancer patients, allowing us to compare the differences that 
potentially exist between each patient. Moreover, the use of an 
ELISA assay has several benefits for use in clinical practice; 
it is easy, quantitative and a small amount of the body fluid is 
required. Previous studies have suggested that MMP-2 and -9 
be used as diagnostic markers in tissue and plasma samples. 
However, this is the first study to use malignant body fluids 
from breast cancer to evaluate MMPs as possible diagnostic 
markers. In particular, our results suggest that MMP-2 is a 
highly sensitive diagnostic marker for metastatic breast cancer 
patients. The limitations of the current study are: i) the patient 
heterogeneity, ii) the study is retrospective with a small sample 
size, and iii) the determination of the assay cut-off level is 
arbitrary. Patient heterogeneity with tumor heterogeneity is 
the essential problem of translational research. In our study, 
patients with relatively homogeneous clinical features were 
selected. The patients were required to have clinically evident 
malignant ascites or pleural effusion regardless of cytology 
results, considering the false negativity of body fluid cytology. 
Since systemic chemotherapy after body fluid formation 
may affect prognosis, we selected patients who had received 
active systemic chemotherapy prior to body fluid formation. 
Therefore, patients who developed ascites or pleural effusion 
at the time of breast cancer diagnosis were excluded. Multiple 
sites of metastasis were also observed, including a minimum 
of 1 visceral metastasis from the breast cancer. All the patients 
were previously heavily pretreated with active systemic treat-
ment. In addition, this study is the first study to evaluate the 
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proof-of-concept of whether the biomarker in the body fluid 
may work in clinical practice and also the feasibility of ELISA 
for stratifying the patients. In almost all the patients who 
develop body fluids, the fluid examination is easily performed 
in clinical practice, and the collection of body fluid is feasible. 
Gathering the fluid provides biological information, which may 
be of clinical use, and therefore this practice is worthwhile. 
However, validation with large numbers of prospectively 
collected samples is required for the further clinical develop-
ment of these novel body fluid biomarkers.
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